These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 3546358)

  • 1. Medical treatment of hyperprolactinaemic disorders.
    Ferrari C; Crosignani PG
    Hum Reprod; 1986 Dec; 1(8):507-14. PubMed ID: 3546358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperprolactinemia: pathophysiology and management.
    Verhelst J; Abs R
    Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine receptor agonists for treating prolactinomas.
    Colao A; di Sarno A; Pivonello R; di Somma C; Lombardi G
    Expert Opin Investig Drugs; 2002 Jun; 11(6):787-800. PubMed ID: 12036422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hyperprolactinemia and prolactinomas. Results of surgical and drug therapy].
    Brabant G; Brennecke I; Herrmann H; Friedrich H; Wagner TO; von zur Mühlen A; Hesch RD
    Dtsch Med Wochenschr; 1985 Oct; 110(41):1564-7. PubMed ID: 4042883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on prolactinomas. Part 2: Treatment and management strategies.
    Wong A; Eloy JA; Couldwell WT; Liu JK
    J Clin Neurosci; 2015 Oct; 22(10):1568-74. PubMed ID: 26243714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of terguride on prolactin levels in normal, puerperal and hyperprolactinaemic women.
    Venturini PL; Horowski R; Valenzano M; Costantini S; Fasce V; Gorlero F; Rainer E; De Cecco L
    Eur J Clin Pharmacol; 1986; 30(2):195-7. PubMed ID: 3709645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current treatment issues in female hyperprolactinaemia.
    Crosignani PG
    Eur J Obstet Gynecol Reprod Biol; 2006 Apr; 125(2):152-64. PubMed ID: 16288952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of hyperprolactinemia and acromegaly with lisuride].
    Berezin M; Elchalal U; Olchovsky D
    Harefuah; 1989 Jun; 116(12):634-7. PubMed ID: 2792946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Medical treatment of hyperprolactinemic states using lisuride, a prolonged-action dopaminergic].
    Zárate A; Fonseca ME; Moran C; Miranda R
    Gac Med Mex; 1988; 124(3-4):107-9. PubMed ID: 2905312
    [No Abstract]   [Full Text] [Related]  

  • 11. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
    Hamilton DK; Vance ML; Boulos PT; Laws ER
    Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychotic reactions during treatment of pituitary tumours with dopamine agonists.
    Turner TH; Cookson JC; Wass JA; Drury PL; Price PA; Besser GM
    Br Med J (Clin Res Ed); 1984 Oct; 289(6452):1101-3. PubMed ID: 6435792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term pergolide treatment of hyperprolactinemic patients previously unsuccessfully treated with dopaminergic drugs.
    Berezin M; Avidan D; Baron E
    Isr J Med Sci; 1991 Jul; 27(7):375-9. PubMed ID: 2071373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine agonists in the treatment of hyperprolactinemia. Comparison between bromocriptine and lisuride.
    Stracke H; Heinlein W; Horowski R; Schatz H
    Arzneimittelforschung; 1986 Dec; 36(12):1834-6. PubMed ID: 3566845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation and treatment of hyperprolactinaemia in women of childbearing age.
    Marek J; Zivný J; Srámková J; Kucera E; Kobilková J
    Acta Univ Palacki Olomuc Fac Med; 1981; 101():110-7. PubMed ID: 6242681
    [No Abstract]   [Full Text] [Related]  

  • 16. Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR).
    Schettini G; Lombardi G; Merola B; Colao A; Miletto P; Caruso E; Lancranjan I
    Clin Endocrinol (Oxf); 1990 Aug; 33(2):161-9. PubMed ID: 2225475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperprolactinemia and prolactinomas.
    Mancini T; Casanueva FF; Giustina A
    Endocrinol Metab Clin North Am; 2008 Mar; 37(1):67-99, viii. PubMed ID: 18226731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of hyperprolactinemia with pergolide.
    Mattox JH; Bernstein J; Buckman MT
    Int J Fertil; 1986; 30(4):39-43. PubMed ID: 2890594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolactinomas.
    Couldwell WT; Weiss MH; Laws ER
    N Engl J Med; 2004 Mar; 350(10):1054-7; author reply 1054-7. PubMed ID: 15002121
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of the clinical activity of mesulergine and pergolide in the treatment of hyperprolactinaemia.
    Grossman A; Bouloux PM; Loneragan R; Rees LH; Wass JA; Besser GM
    Clin Endocrinol (Oxf); 1985 May; 22(5):611-6. PubMed ID: 4028459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.